TARA PROTARA THERAPEUTICS INC Disposals and divestitures 8-K Filing 2025 - Asset Sales Protara Therapeutics, Inc. reported positive interim clinical results for its ongoing Phase 2 ADVANCED-2 trial on April 26, 2025, featuring a 100% complete response rate in BCG-Unresponsive patients and a 76% rate in BCG-Naïve patients. The company also held an investor presentation on April 28, 2025, to discuss these findings, which included the data from clinical trials.Get access to all SEC 8-K filings of the PROTARA THERAPEUTICS INC